Verve Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Benchmark

The Relative Strength (RS) Rating for Verve Therapeutics (VERV) entered a new percentile Friday, with an increase from 76 to 83.


As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.

This exclusive rating from Investor’s Business Daily identifies share price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock’s price behavior over the last 52 weeks holds up against all the other stocks in our database.

Over 100 years of market history shows that the best stocks often have an 80 or higher RS Rating as they launch their biggest price moves.

See How IBD Helps You Make More Money In Stocks

While Verve Therapeutics is not near a proper buying range right now, see if it manages to form and break out from a proper base.

The company showed -587% earnings growth last quarter, while sales growth came in at 0%. Look for the next report on or around Oct. 28.

The company holds the No. 218 rank among its peers in the Medical-Biomed/Biotech industry group. Alkermes (ALKS) and Innoviva (INVA) are also among the group’s highest-rated stocks.


Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Improved Technical Action?

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Identify Bases And Buy Points With Pattern Recognition From MarketSmith

Most Related Links :
Business News Governmental News Finance News

Source link